A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

With their lengthening laundry list of health benefits, drugs like Ozempic and Wegovy are showing promise outside of weight loss and diabetes treatments. One of the most exciting off-label uses of ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...